Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Pre-clinical research

Paroxetine improves symptoms of heart failure in mice

Paroxetine  (molecular structure pictured), a selective serotonin reuptake inhibitor (SSRI), improves symptoms of heart failure in mice, research finds


The antidepressant paroxetine (molecular structure pictured) inhibits G-protein-coupled receptor kinase 2, an enzyme that hastens the onset of heart failure

In a failing human heart there is an increase in the presence of G-protein-coupled receptor kinase 2 (GRK2). This enzyme hastens the onset of heart failure.

Researchers have observed that GRK2 could be inhibited by the selective serotonin reuptake inhibitor (SSRI) paroxetine. Therefore, mice with heart failure were used to compare paroxetine with fluoxetine, an SSRI that does not inhibit GRK2.

After two weeks, the mice given paroxetine had improved left ventricular function and structure and a regression of many signs of heart failure, in a study published in Science Translational Medicine[1] (online, 4 March 2015). Mice in the fluoxetine group had continued deterioration, indicating that the effect is independent of the serotonin system. In addition, paroxetine was more effective than beta blockers, which the authors note is currently the gold-standard human treatment.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20068111

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.